Utilizing innovative forms of drug delivery technologies, Delpor is a clinical stage life sciences company developing new therapeutic products anchored in already approved drugs. The firms technologies enable the sustained release of drugs through a small, non-mechanical (passive), subcutaneous implant device that can be implanted during a simple, 10-minute, in-office, procedure using local anesthetic. The firm's system has the capability to deliver small molecules, peptides, and proteins within a predefined therapeutic window over several months while maintaining zero-order release. Included in the firm's system is use of Prozor for the delivery of antipsychotics and other small molecule drugs from a non-mechanical implantable drug delivery device; NANOPOR, a non-mechanical implantable drug delivery device in which sustained release is provided by membrane architecture; and Delos PUMP, a self-contained and electro-osmotically driven implantable drug delivery device to deliver drugs in predetermined patterns, The benefits of such delivery include improved patient adherence to the medication, as well as patient convenience in the case where frequent injections are required. The firm's delivery technologies typically result in fewer AEs and improved efficacy due to a smoother pharmacokinetic profile without any peaks or troughs. Principals of the firm are currently addressing 6-12 month formulations of several drugs targeting various chronic conditions
